1.
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands
A cost-consequence model of using the 21-gene assay to identify patients with early-stage node-positive breast cancer who benefit from adjuvant chemotherapy in the Netherlands ...
2.
3.
4.
5.
Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands
6.
7.
8.
9.
